Literature DB >> 8946133

Diagnosis and treatment of pulmonary artery hypertension.

R J Barst1.   

Abstract

It is intellectually unsatisfying for physicians to admit that a group of patients remain for whom no cure is available in modern medicine. Despite our inability to cure pulmonary artery hypertension, therapeutic medical and surgical advances over the past decade have resulted in significant improvements in the outcome for children with various forms of pulmonary hypertension. This review discusses the work-up and evaluation of a child who presents with pulmonary artery hypertension and discusses recent therapeutic advances. The roles of anticoagulation, vasodilator therapy (including inhaled nitric oxide and chronic intravenous prostacyclin), and transplantation are discussed. These therapeutic modalities have improved quality of life, exercise capacity, and pulmonary hemodynamics as well as long-term survival for children with pulmonary hypertension.

Entities:  

Mesh:

Year:  1996        PMID: 8946133     DOI: 10.1097/00008480-199610000-00016

Source DB:  PubMed          Journal:  Curr Opin Pediatr        ISSN: 1040-8703            Impact factor:   2.856


  6 in total

1.  Prostacyclin-analog therapy in sickle cell pulmonary hypertension.

Authors:  Nargues A Weir; Rehan Saiyed; Shoaib Alam; Anna Conrey; Himanshu D Desai; M Patricia George; Jennifer H Keeley; Elizabeth S Klings; Alem Mehari; James G Taylor; Caterina P Minniti; Gregory J Kato
Journal:  Haematologica       Date:  2017-01-25       Impact factor: 9.941

2.  [Pulmonary hypertension: Possible genetic causes and therapeutic options].

Authors:  E Grünig; C A Eichstaedt; N Ehlken; E Mayer; H Klose
Journal:  Herz       Date:  2015-05       Impact factor: 1.443

Review 3.  Regulation and interactions in the activation of cell-associated plasminogen.

Authors:  H Myöhänen; A Vaheri
Journal:  Cell Mol Life Sci       Date:  2004-11       Impact factor: 9.261

Review 4.  Recognition and management of pulmonary hypertension.

Authors:  J C Wanstall; T K Jeffery
Journal:  Drugs       Date:  1998-12       Impact factor: 9.546

5.  A multicenter, retrospective study of patients with pulmonary arterial hypertension transitioned from parenteral prostacyclin therapy to inhaled iloprost.

Authors:  Richard N Channick; Robert P Frantz; Steven M Kawut; Harold Palevsky; Ramagopal Tumuluri; Roxana Sulica; Paula O Lauto; Wade W Benton; Bennett de Boisblanc
Journal:  Pulm Circ       Date:  2013-04       Impact factor: 3.017

Review 6.  Treatment of pediatric pulmonary hypertension.

Authors:  Amy Hawkins; Robert Tulloh
Journal:  Vasc Health Risk Manag       Date:  2009-06-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.